Literature DB >> 6555016

Synergy of combinations of vancomycin, gentamicin, and rifampin against methicillin-resistant, coagulase-negative staphylococci.

F D Lowy, D S Chang, P R Lash.   

Abstract

The activity of combinations of vancomycin (2 or 10 micrograms/ml), gentamicin (0.3 micrograms/ml), and rifampin (0.03 micrograms/ml) against methicillin-resistant, coagulase-negative staphylococcal isolates was determined by the time-kill method. Combinations of rifampin with gentamicin or with vancomycin 2 micrograms/ml demonstrated enhanced killing against 13 of 17 and 13 of 25 strains, respectively. However, rifampin-resistant strains were selected with the latter combination in the remaining 12 of 25 studies.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6555016      PMCID: PMC185010          DOI: 10.1128/AAC.23.6.932

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Susceptibility of Staphylococcus aureus and Staphylococcus epidermidis to 65 antibiotics.

Authors:  L D Sabath; C Garner; C Wilcox; M Finland
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

2.  Comparative synergistic activity of nafcillin, oxacillin, and methicillin in combination with gentamicin against.

Authors:  R H Glew; R S Millering; C Wennersten
Journal:  Antimicrob Agents Chemother       Date:  1975-06       Impact factor: 5.191

3.  Interaction between vancomycin and rifampin against Staphylococcus aureus.

Authors:  C Watanakunakorn; J C Guerriero
Journal:  Antimicrob Agents Chemother       Date:  1981-06       Impact factor: 5.191

4.  Rapid microassay of gentamicin, kanamycin, neomycin, streptomycin, and vancomycin in serum or plasma.

Authors:  L D Sabath; J I Casey; P A Ruch; L L Stumpf; M Finland
Journal:  J Lab Clin Med       Date:  1971-09

5.  Single and combination antibiotic therapy of Staphylococcus aureus experimental endocarditis: emergence of gentamicin-resistant mutants.

Authors:  M H Miller; M A Wexler; N H Steigbigel
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

6.  Antibiotic activity in vitro against methicillin-resistant Staphylococcus epidermidis and therapy of an experimental infection.

Authors:  F D Lowy; J A Walsh; M M Mayers; R S Klein; N H Steigbigel
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

7.  Therapy of methicillin-resistant Staphylococcus epidermidis experimental endocarditis.

Authors:  F D Lowy; M A Wexler; N H Steigbigel
Journal:  J Lab Clin Med       Date:  1982-07

8.  Rifampin therapy of Staphylococcus epidermidis. Use in infections from indwelling artificial devices.

Authors:  G L Archer; M J Tenenbaum; H B Haywood
Journal:  JAMA       Date:  1978-08-25       Impact factor: 56.272

  8 in total
  12 in total

1.  Aminoglycoside therapy: current and prospective uses.

Authors:  J E Leggett
Journal:  Tex Heart Inst J       Date:  1990

2.  Vancomycin: renewed interest in an old drug.

Authors:  B B Farber
Journal:  Eur J Clin Microbiol       Date:  1984-02       Impact factor: 3.267

3.  In vitro susceptibilities of four species of coagulase-negative staphylococci.

Authors:  R J Fass; V L Helsel; J Barnishan; L W Ayers
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

Review 4.  Current problems of chemotherapy of infections with coagulase-negative staphylococci.

Authors:  A J Davies; J W Stone
Journal:  Eur J Clin Microbiol       Date:  1986-06       Impact factor: 3.267

5.  Penicillin-induced effects on streptomycin uptake and early bactericidal activity differ in viridans group and enterococcal streptococci.

Authors:  M H Miller; M A el-Sokkary; S A Feinstein; F D Lowy
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

6.  Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia.

Authors:  T Q Tan; E O Mason; C N Ou; S L Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

Review 7.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

8.  Comparison of cefazolin, cefamandole, vancomycin, and LY146032 for prophylaxis of experimental Staphylococcus epidermidis endocarditis.

Authors:  L J Wheat; J W Smith; J Reynolds; A T Bemis; T Treger; J A Norton
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

9.  Effects of powdered rifampin and vancomycin solutions on biofilm production of staphylococcus aureus on orthopedic implants.

Authors:  Christian Douthit; Brent Gudenkauf; Abdul Hamood; Nithya Mudaliar; Cyrus Caroom; Mark Jenkins
Journal:  J Clin Orthop Trauma       Date:  2019-10-13

10.  Antibiotics release from cement spacers used for two-stage treatment of implant-associated infections after total joint arthroplasty.

Authors:  Annett Klinder; Sarah Zaatreh; Martin Ellenrieder; Sylvio Redanz; Andreas Podbielski; Tobias Reichel; Hans Bösebeck; Wolfram Mittelmeier; Rainer Bader
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2018-10-12       Impact factor: 3.368

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.